ClinicalTrials.gg
CompletedNCT06553287Updated Aug 14, 2024

Safety, Tolerability and Pharmacokinetics of LNK01004 Ointment in Adults With Atopic Dermatitis.

A Phase 1 interventional study of LNK01004 ointment 0.3% and LNK01004 ointment 1.0% in Atopic Dermatitis, sponsored by Lynk Pharmaceuticals Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-14.

Sponsored by Lynk Pharmaceuticals Co., Ltd · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Jul 2023, registered Aug 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 207 studies in Dermatitis, Atopic with a site in China — 65 open to participants now, 83 under way, 29 of them phase 3. Dermatitis, Atopic · China.

Enrollment
170th of 191
28 · median 163
Started
2023
with 38 others
Phase 1
39 of 207
15 open now
Registered
123rd of 207
by date

Among the 207 studies in Dermatitis, Atopic with a site in China, this one is the 170th largest by enrollment of the 191 interventional ones that give a count, is one of 39 that started in 2023, is one of 39 in phase 1, and was the 123rd registered.

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

65 of the 207 studies in Dermatitis, Atopic with a site in China are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 207 studies in Dermatitis, Atopic with a site in China, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the Safety, Tolerability, and Pharmacokinetics of LNK01004 ointment (0.3%, 1.0%, and 1.5%) vs vehicle twice daily (BID) in Adults Patients with Atopic Dermatitis.

Read the detailed description

This is a multicenter, randomized, double-blind, vehicle-controlled, dose-escalation study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LNK01004 ointment twice daily (BID) in participants with Mild to Moderate atopic dermatitis as compared with vehicle cream BID.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants were diagnosed with atopic dermatitis (AD) for at least 6 months.
  • Participants with an Investigator's Global Assessment (IGA) score of 2 to 3 at screening and baseline.
  • Participants with body surface area (BSA) of AD involvement, excluding the scalp, face, and intertriginous areas, of 3% to 20% at screening and baseline.
  • of 18.0-30.0 kg/m2, with body weight ≥ 50 kg for man and ≥ 40 kg for woman.
  • Be willing to comply with the study lifestyle restraints, e.g., no washing of the administered area within 6 hours of study drug administration, no sweaty exercise.

Exclusion criteria

Exclusion Criteria:

  • Participants with a physical condition which, in the Investigator´s opinion, might interfere with the assessment of atopic dermatitis or expose the patient to an unacceptable risk by study participation.
  • Participants with current evidence of any acute skin infection with a history of recurrent or chronic severe skin infection.
  • Participants with known allergies to components or of the test drug.
  • Participants who are pregnant, nursing, or planning a pregnancy during the study period.
  • Systemic or immunomodulating drugs (eg, oral or injectable , mycophenolate mofetil, PDE4 inhibitor) used for atopic dermatitis within 4 weeks or 5 half-lives of baseline (whichever is longer).
  • Participants with the following hematologic abnormities at screening:
  • Leukocytes \< 3.0 × 10\^9/L.
  • Neutrophils \< lower limit of normal.
  • \< 10 g/dL.
  • Lymphocytes \< 0.8 × 10\^9/L
  • \< 100 × 10\^9/L.
  • (ALT) or aspartate aminotransferase (AST) ≥ 1.5 × .
  • TBiL ≥ 1.5 × ULN, or ULN \< TBiL \< 1.5 × ULN but judged by the investigator to be abnormal ;
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    LNK01004 ointment 0.3%

    Participants will receive LNK01004 ointment 0.3% twice daily

    Drug: LNK01004 ointment 0.3%

  • Experimental
    LNK01004 ointment 1.0%

    Participants will receive LNK01004 ointment 1.0% twice daily

    Drug: LNK01004 ointment 1.0%

  • Experimental
    LNK01004 ointment 1.5%

    Participants will receive LNK01004 ointment 1.5% twice daily

    Drug: LNK01004 ointment 1.5%

  • Experimental
    Vehicle

    Participants will receive vehicle BID

    Drug: Vehicle BID

Interventions

  • DrugLNK01004 ointment 0.3%

    LNK01004 ointment 0.3% for topical application

  • DrugLNK01004 ointment 1.0%

    LNK01004 ointment 1.0% for topical application

  • DrugLNK01004 ointment 1.5%

    LNK01004 ointment 1.5% for topical application

  • DrugVehicle BID

    Inactive vehicle matched to LNK01004 ointment for topical application.

06

What researchers measure

Primary outcomes

  1. Treatment-Emergent Adverse Events (TEAE)

    Number of participants with at least one TEAE.

    Time frame: Baseline up to week 4

Secondary outcomes

  1. Maximum concentration (Cmax) for LNK01004 in plasma

    Cmax is defined as the maximum observed plasma concentration for LNK01004

    Time frame: Day1 and Day 7

  2. Area under plasma concentration versus time curve, time zero to infinity

    The area under the plasma concentration-time curve is a method of measurement of the total exposure of a drug in plasma

    Time frame: Day 1 and Day7

  3. Mean Percentage Change From Baseline in Eczema Area and Severity Index (EASI) Score

    The EASI is an instrument to measure the severity and extent of AD. The body is first divided into 4 areas: head (10% of skin), arms (20%), trunk (30%), and legs (40%). Then, the area affected is scored from 0 (0% involvement) to 6 (90-100% involvement), and severity is scored from 0 ('none') to 3 ('severe'). The EASI combines the area affected and severity ratings to get a final composite score ranging from 0 (no disease) to 72 (maximal disease). Note that palms and soles were treated as appropriate but were not counted towards any measurements of EASI.

    Time frame: Baseline and Weeks 1, 2, and 4

  4. Number of Participants Achieving a 75% Decrease From Baseline in EASI Score (EASI-75)

    The number of participants with a decrease of at least 75% from the baseline EASI total score is presented. The EASI is an instrument to measure the severity and extent of AD. The body is first divided into 4 areas: head (10% of skin), arms (20%), trunk (30%), and legs (40%). Then, the area affected is scored from 0 (0% involvement) to 6 (90-100% involvement), and severity is scored from 0 ('none') to 3 ('severe'). The EASI combines the area affected and severity ratings to get a final composite score ranging from 0 (no disease) to 72 (maximal disease), with positive results indicating an increase from baseline in EASI total score (i.e., increased symptoms) and negative results indicating a decrease from baseline score (i.e., decreased symptoms). Note that palms and soles were treated as appropriate but were not counted towards any measurements of EASI.

    Time frame: Baseline and Weeks 1, 2, and 4

  5. Number of Participants Achieving ≥4-Point Improvement in WI-NRS Pruritus Score

    The number of participants achieving a ≥4-point improvement from Baseline in WI-NRS score is presented. The WI-NRS is a simple, single item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the subject experienced in the previous 24 hours. Higher scores indicate greater symptom severity.

    Time frame: Baseline and Weeks 1, 2, and 4

  6. Percentage of Participants Achieving an Investigator's Global Assessment (IGA) Score of 0 to 1 Who Have an Improvement of ≥ 2 Points From Baseline

    IGA is an assessment scale used to determine severity of atopic dermatitis (AD) and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response was an IGA score of 0 (clear) or 1 (almost clear). An IGA responder was defined as a participant achieving an IGA score of 0 to 1 and an IGA score improvement at least 2 from baseline.

    Time frame: Baseline and Weeks 1, 2, and 4

07

Study locations

1 site
  • Hospital for skin diseases, Institute of Dermatology, Chinese Academy of Medical Sciences.
    Nanjing, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Jun 2024, 11 months.

Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 11 months is close to that.

Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2024
First posted
Aug 14, 2024
StartActual
Jul 12, 2023
Primary completionActual
Jun 18, 2024
CompletionActual
Jun 18, 2024
Last update
Aug 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06553287
Lead sponsor
Lynk Pharmaceuticals Co., Ltd
Responsible party
Sponsor
First posted
Aug 14, 2024
Start date
Jul 12, 2023
Primary completion
Jun 18, 2024
Completion
Jun 18, 2024
Last update
Aug 14, 2024

Study contacts

Qianjin Lu
principal investigator · Hospital for skin diseases, Institute of Dermatology, Chinese Academy of Medical Sciences.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion